What Is Selank? The Tuftsin-Based Anxiolytic Peptide

What Selank actually is

Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that the body cleaves from the Fc region of immunoglobulin G during normal immune signaling. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences extended and modified tuftsin's structure to create Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a heptapeptide designed to resist rapid enzymatic breakdown while retaining activity at receptors implicated in stress response and immune modulation (Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress).

This is not a repackaged tuftsin product. The added proline-glycine-proline sequence changes its pharmacokinetic profile and, according to the animal literature, its behavioral effects. Selank belongs to a small family of tuftsin-derived peptides studied by the same research groups, including TP-7, which was evaluated separately for anxiety-related behavior (Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight). Selank is a distinct molecule from Semax, another Russian-developed peptide sometimes stacked with it; the two are not interchangeable, and readers comparing them should see our Semax vs. Selank comparison.

Where was Selank actually developed and tested?

This is the detail most secondary sources gloss over, and it matters for how much weight to give the evidence. The foundational Selank research was conducted by Russian institutions, primarily the Institute of Molecular Genetics (Russian Academy of Sciences) and affiliated pharmacology and physiology departments, published mostly in Russian-language journals such as Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, Eksperimental'naia i klinicheskaia farmakologiia, and Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. Early behavioral pharmacology work through the 2000s established dose-response patterns in animals (Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress; naloxone-blocked depriming effect of anxiolytic selank).

A Russian clinical study on generalized anxiety disorder and neurasthenia reported symptomatic improvement with Selank treatment (Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia). This is real clinical-population evidence, not just rodent data, but it comes from a single country's research infrastructure, published in a non-English journal, without the independent replication, large sample sizes, or FDA/EMA regulatory review that would let a US clinician treat it as practice-changing. No equivalent trial has been conducted or published by Western academic centers or under FDA IND oversight, as far as the cited literature shows. That gap is the central limitation of the entire Selank evidence base, and it is why every downstream claim about anxiety, mood, or cognition needs a "studied in Russia, not replicated elsewhere" qualifier attached to it. For a deeper look at the anxiety-specific data, see Selank anxiety evidence.

What effects does the research actually claim?

The published literature attributes several effects to Selank, almost all from animal models:

Anxiolytic-like behavior. Multiple rodent studies describe reduced anxiety-like behavior after Selank administration, with effects partially blocked by naloxone, suggesting involvement of opioid signaling pathways (naloxone-blocked depriming effect; role of opioid system in anti-anxiety effect of selank).

Effects on monoamine systems. Selank has been shown in mouse and rat brain tissue to alter serotonin and other monoamine metabolism, which is the proposed biochemical basis for its behavioral effects (comparison of selank and tuftsin on serotonin metabolism; effects of heptapeptide selank on monoamine content).

Memory and learning in animal models of impairment. Several studies report that Selank preserved or restored learning and memory performance in rats and monkeys subjected to neurotoxic or pharmacological memory disruption (compensatory and antiamnestic effects of Selank in monkeys; experimental optimization of learning and memory by selank; protective effect of selank on mnestic function).

Immune and gene expression effects. As a tuftsin derivative, Selank has been studied for effects on cytokine and chemokine gene expression in mouse spleen tissue and on gastric mucosal homeostasis (expression of inflammation-related genes in mouse spleen under selank; selank and its metabolites in gastric mucosa). This immune angle is covered in more depth at Selank immune research.

None of these mechanisms have been confirmed in a placebo-controlled human trial published in an internationally indexed, English-language journal with the sample size and blinding rigor that FDA or EMA reviewers would require for an approval decision. That distinction, animal mechanism versus confirmed human clinical benefit, is the one most marketing copy blurs.

Is Selank legal, and is it FDA approved?

Selank has no FDA-approved indication for any condition, human or veterinary. It is not listed on the FDA's 503A bulk drug substances list used for compounding (FDA bulk drug substances framework), which means a compounding pharmacy cannot lawfully use it as a compounding ingredient under that pathway. This page makes no claim about Selank's status under any other FDA category, and makes no claim that Selank is approved in any country outside the United States. Regulatory status can shift; check the current listing before relying on this summary. For the most current regulatory snapshot, see the FDA Peptide Status Tracker and the dedicated Selank FDA status page.

Anyone using Selank in the US today is doing so outside any FDA-reviewed pathway. That is a materially different situation from an off-label prescription of an FDA-approved drug, where at least the manufacturing, purity, and human safety data have passed regulatory review for some indication.

What Selank is not, and where the evidence actually stops

Evidence-boundary map for Selank claims

Use this table as a check before accepting any claim you see elsewhere framed as settled fact. If a source states a Selank human benefit without citing a specific clinical trial, that claim is currently unsupported by the evidence available to us.

When should someone seek care instead of researching a peptide?

Anxiety symptoms that involve panic attacks, suicidal thoughts, significant functional impairment, or coexisting substance use need evaluation by a licensed clinician, not a peptide protocol. FDA-approved treatments for generalized anxiety disorder, including SSRIs, SNRIs, and buspirone, have far larger and more rigorous human trial bases than Selank does; see Selank vs. SSRIs and Selank vs. benzodiazepines for direct evidence comparisons. If anxiety is acute, worsening, or accompanied by chest pain, difficulty breathing, or thoughts of self-harm, that is an urgent care or emergency situation, not a research question.

The bottom line

Selank is a real, well-characterized synthetic peptide with a documented development history in Russian pharmacology research, not a fringe internet invention. But the strength of that history is almost entirely preclinical, and the one clinical trial in the cited literature comes from a single national research system without independent international replication. Anyone considering Selank should treat the animal and single-country clinical data as a starting hypothesis, not a proven human treatment, and should understand that no US regulatory body has reviewed it for safety or efficacy in any indication. For dosing format and route questions, see Selank dosing: nasal vs. injection; for a broader accounting of what the evidence base does and does not support, see Selank evidence quality.